如何应用分子遗传学检测评估疑似或确诊骨髓增生异常综合征患者
本文综述分子遗传学检测在疑似或确诊骨髓增生异常综合征(MDS)患者中的应用。MDS诊断困难时,特定体细胞突变模式可提示疾病进展高可能性并允许临时诊断,但老年健康人群常见衰老相关突变(DNMT3A、TET2、ASXL1)可造成诊断不确定性;部分获得性突变还影响风险分层和治疗选择。
要点
- MDS诊断困难时,特定体细胞突变模式在血细胞减少患者中提示疾病进展高可能性,可允许临时诊断。
- 老年健康人群常见白血病相关驱动基因突变(尤其DNMT3A、TET2、ASXL1),在血细胞减少患者中可致诊断不确定性。
- 部分获得性突变影响已确诊MDS患者的风险分层,并可指导治疗选择。
核心结论
- 特定体细胞突变模式在血细胞减少患者中提示疾病进展高可能性,即使形态学发育异常和其他诊断标准缺失,也可允许MDS的临时诊断。
- 部分获得性突变影响已确诊MDS患者的风险分层,并可指导治疗选择。
- 关于特定突变的临床意义仍有许多未解问题,临床医生解读测序结果的把握度差异很大。
研究设计与样本
- 综述,回顾分子遗传学检测在疑似或确诊MDS患者中的应用。
主要发现
- MDS患者中已发现超过40个基因存在反复体细胞突变。
- 许多老年健康个体也携带白血病相关驱动基因的体细胞突变,尤其DNMT3A、TET2和ASXL1。
- 在血细胞减少患者中检测到常见衰老相关突变可导致诊断不确定性。
- 特定体细胞突变模式在血细胞减少患者中提示疾病进展高可能性,可允许临时诊断MDS。
- 部分获得性突变影响已确诊MDS患者的风险分层并指导治疗选择。
局限性
- 关于特定突变的临床意义仍有许多未解问题。
- 临床医生解读测序结果的把握度差异很大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) can be difficult to diagnose, especially when morphological changes in blood and marrow cells are minimal, myeloblast proportion is not increased, and the karyotype is normal. The discovery of >40 genes that are recurrently somatically mutated in MDS patients raised hope that molecular genetic testing for these mutations might help clarify the diagnosis in ambiguous cases where patients present with cytopenias and nondiagnostic marrow morphological findings. However, many older healthy individuals also harbor somatic mutations in leukemia-associated driver genes, especially in DNMT3A, TET2, and ASXL1, and detection of common aging-associated mutations in a cytopenic patient can cause diagnostic uncertainty. Despite this potential confounding factor, certain somatic mutation patterns when observed in cytopenic patients confer a high likelihood of disease progression and may allow a provisional diagnosis of MDS even if morphologic dysplasia and other diagnostic criteria are absent. A subset of acquired mutations also influences risk stratification of patients with an established MDS diagnosis and can inform treatment selection. Many unanswered questions remain about the implications of specific mutations, and clinicians also vary widely in their comfort with interpreting sequencing results. Here, I review the use of molecular genetic assays in patients with possible MDS or diagnosed MDS.
引用
- Steensma DP. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. Blood. 2018. PMID: 30185432. doi:10.1182/blood-2018-06-860882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。